Cellosaurus EB2 (CVCL_1186)

Cell line name EB2
Synonyms EB-2; Epstein-Barr-2
Accession CVCL_1186
Resource Identification Initiative To cite this cell line use: EB2 (RRID:CVCL_1186)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Microsatellite instability: Instable (MSI-low) (Sanger).
Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Epstein-Barr virus-related Burkitt lymphoma (NCIt: C27694)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP

Markers:
AmelogeninX
CSF1PO10,12
D13S31711,13
D16S5398,10
D5S8188,12
D7S82010,12
TH019,9.3
TPOX8,9
vWA14,16
Publications

PubMed=14284371; DOI=10.1038/bjc.1965.11
Epstein M.A., Barr Y.M., Achong B.G.
The behaviour and morphology of a second tissue culture strain (EB2) of lymphoblasts from Burkitt's lymphoma.
Br. J. Cancer 19:108-115(1965)

PubMed=6018567
Miles C.P., O'Neill F.
Chromosome studies of 8 in vitro lines of Burkitt's lymphoma.
Cancer Res. 27:392-402(1967)

PubMed=4894370; DOI=10.1002/1097-0142(196908)24:2<211::AID-CNCR2820240202>3.0.CO;2-3
Southam C.M., Burchenal J.H., Clarkson B.D., Tanzi A., Mackey R., McComb V.
Heterotransplantability of human cell lines derived from leukemia and lymphomas into immunologically tolerant rats.
Cancer 24:211-222(1969)

PubMed=4736620; DOI=10.1111/j.1469-1809.1973.tb00588.x
Povey S., Gardiner S.E., Watson B., Mowbray S., Harris H., Arthur E., Steel C.M., Blenkinsop C., Evans H.J.
Genetic studies on human lymphoblastoid lines: isozyme analysis on cell lines from forty-one different individuals and on mutants produced following exposure to a chemical mutagen.
Ann. Hum. Genet. 36:247-266(1973)

PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x
Povey S., Jeremiah S., Arthur E., Steel M., Klein G.
Differences in genetic stability between human cell lines from patients with and without lymphoreticular malignancy.
Ann. Hum. Genet. 44:119-133(1980)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=8515068
Jain V.K., Judde J.-G., Max E.E., Magrath I.T.
Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
J. Immunol. 150:5418-5428(1993)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections ATCC; HTB-61
Cell line databases/resources CCLE; EB2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
Cosmic-CLP; 906846
GDSC; 906846
IGRhCellID; EB2
LINCS_LDP; LCL-2031
Ontologies CLO; CLO_0002873
EFO; EFO_0002173
Chemistry resources ChEMBL-Cells; CHEMBL3308867
ChEMBL-Targets; CHEMBL2366338
Gene expression databases GEO; GSM886992
GEO; GSM888061
GEO; GSM1669747
Polymorphism and mutation databases Cosmic; 906846
Cosmic; 1818342